Efficacy and safety of two dosages of canrenone as add-on therapy in hypertensive patients taking ace-inhibitors or angiotensin II receptor blockers and hydrochlorothiazide at maximum dosage in a randomized clinical trial: The ESCAPE-IT trial

G. Derosa; P. Maffioli; M. D'Avino; C. Sala; A. Mugellini; V. Vulpis; S. Felis; L. Guasti; R. Sarzani; A. Bestetti; M. Vanasia; G. Gaudio; the ESCAPE-IT Trial Investigators group

doi:10.1111/1755-5922.12235

Efficacy and safety of two dosages of canrenone as add-on therapy in hypertensive patients taking ace-inhibitors or angiotensin II receptor blockers and hydrochlorothiazide at maximum dosage in a randomized clinical trial: The ESCAPE-IT trial

G. Derosa, P. Maffioli, M. D'Avino, C. Sala, A. Mugellini, V. Vulpis, S. Felis, L. Guasti, R. Sarzani, A. Bestetti, M. Vanasia, G. Gaudio, the ESCAPE-IT Trial Investigators group

Research output: Contribution to journal › Article

Original language	English
Pages (from-to)	47-54
Number of pages	8
Journal	Cardiovascular Therapeutics
Volume	35
Issue number	1
DOIs	https://doi.org/10.1111/1755-5922.12235
Publication status	Published - 2017

Keywords

Angiotensin II receptor blockers
Angiotensin-converting enzyme inhibitors
Canrenone
Hydrochlorothiazide
Hypertension
aldosterone
angiotensin receptor antagonist
brain natriuretic peptide
canrenone
creatinine
dipeptidyl carboxypeptidase inhibitor
galectin 3
hydrochlorothiazide
potassium
triacylglycerol
urea
uric acid
angiotensin 1 receptor antagonist
antihypertensive agent
biological marker
mineralocorticoid antagonist
thiazide diuretic agent
add on therapy
Article
blood pressure
controlled study
drug dose comparison
drug efficacy
drug safety
drug tolerability
drug withdrawal
essential hypertension
estimated glomerular filtration rate
female
glucose blood level
heart rate
human
insulin resistance
major clinical study
male
multicenter study
open study
parallel design
phase 4 clinical trial
priority journal
pulse pressure
randomized controlled trial
side effect
urea blood level
aged
blood
clinical trial
combination drug therapy
comparative study
drug effects
hypertension
Italy
middle aged
pathophysiology
time factor
treatment outcome
Aged
Angiotensin II Type 1 Receptor Blockers
Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Agents
Biomarkers
Blood Pressure
Drug Therapy, Combination
Female
Humans
Male
Middle Aged
Mineralocorticoid Receptor Antagonists
Sodium Chloride Symporter Inhibitors
Time Factors
Treatment Outcome

Cite this

Derosa, G., Maffioli, P., D'Avino, M., Sala, C., Mugellini, A., Vulpis, V., Felis, S., Guasti, L., Sarzani, R., Bestetti, A., Vanasia, M., Gaudio, G., & group, T. ESCAPE-IT. T. I. (2017). Efficacy and safety of two dosages of canrenone as add-on therapy in hypertensive patients taking ace-inhibitors or angiotensin II receptor blockers and hydrochlorothiazide at maximum dosage in a randomized clinical trial: The ESCAPE-IT trial. Cardiovascular Therapeutics, 35(1), 47-54. https://doi.org/10.1111/1755-5922.12235

Efficacy and safety of two dosages of canrenone as add-on therapy in hypertensive patients taking ace-inhibitors or angiotensin II receptor blockers and hydrochlorothiazide at maximum dosage in a randomized clinical trial: The ESCAPE-IT trial. / Derosa, G.; Maffioli, P.; D'Avino, M.; Sala, C.; Mugellini, A.; Vulpis, V.; Felis, S.; Guasti, L.; Sarzani, R.; Bestetti, A.; Vanasia, M.; Gaudio, G.; group, the ESCAPE-IT Trial Investigators.

In: Cardiovascular Therapeutics, Vol. 35, No. 1, 2017, p. 47-54.

Research output: Contribution to journal › Article

Derosa, G , Maffioli, P, D'Avino, M, Sala, C, Mugellini, A, Vulpis, V, Felis, S, Guasti, L, Sarzani, R , Bestetti, A, Vanasia, M, Gaudio, G & group, TESCAPE-ITTI 2017, 'Efficacy and safety of two dosages of canrenone as add-on therapy in hypertensive patients taking ace-inhibitors or angiotensin II receptor blockers and hydrochlorothiazide at maximum dosage in a randomized clinical trial: The ESCAPE-IT trial', Cardiovascular Therapeutics, vol. 35, no. 1, pp. 47-54. https://doi.org/10.1111/1755-5922.12235

Derosa G , Maffioli P, D'Avino M, Sala C, Mugellini A, Vulpis V et al. Efficacy and safety of two dosages of canrenone as add-on therapy in hypertensive patients taking ace-inhibitors or angiotensin II receptor blockers and hydrochlorothiazide at maximum dosage in a randomized clinical trial: The ESCAPE-IT trial. Cardiovascular Therapeutics. 2017;35(1):47-54. https://doi.org/10.1111/1755-5922.12235

Derosa, G. ; Maffioli, P. ; D'Avino, M. ; Sala, C. ; Mugellini, A. ; Vulpis, V. ; Felis, S. ; Guasti, L. ; Sarzani, R. ; Bestetti, A. ; Vanasia, M. ; Gaudio, G. ; group, the ESCAPE-IT Trial Investigators. / Efficacy and safety of two dosages of canrenone as add-on therapy in hypertensive patients taking ace-inhibitors or angiotensin II receptor blockers and hydrochlorothiazide at maximum dosage in a randomized clinical trial: The ESCAPE-IT trial. In: Cardiovascular Therapeutics. 2017 ; Vol. 35, No. 1. pp. 47-54.

@article{2fb28ab6891c470491816e139a52b5f1,

title = "Efficacy and safety of two dosages of canrenone as add-on therapy in hypertensive patients taking ace-inhibitors or angiotensin II receptor blockers and hydrochlorothiazide at maximum dosage in a randomized clinical trial: The ESCAPE-IT trial",

keywords = "Angiotensin II receptor blockers, Angiotensin-converting enzyme inhibitors, Canrenone, Hydrochlorothiazide, Hypertension, aldosterone, angiotensin receptor antagonist, brain natriuretic peptide, canrenone, creatinine, dipeptidyl carboxypeptidase inhibitor, galectin 3, hydrochlorothiazide, potassium, triacylglycerol, urea, uric acid, angiotensin 1 receptor antagonist, antihypertensive agent, biological marker, mineralocorticoid antagonist, thiazide diuretic agent, add on therapy, Article, blood pressure, controlled study, drug dose comparison, drug efficacy, drug safety, drug tolerability, drug withdrawal, essential hypertension, estimated glomerular filtration rate, female, glucose blood level, heart rate, human, insulin resistance, major clinical study, male, multicenter study, open study, parallel design, phase 4 clinical trial, priority journal, pulse pressure, randomized controlled trial, side effect, urea blood level, aged, blood, clinical trial, combination drug therapy, comparative study, drug effects, hypertension, Italy, middle aged, pathophysiology, time factor, treatment outcome, Aged, Angiotensin II Type 1 Receptor Blockers, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Biomarkers, Blood Pressure, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Mineralocorticoid Receptor Antagonists, Sodium Chloride Symporter Inhibitors, Time Factors, Treatment Outcome",

author = "G. Derosa and P. Maffioli and M. D'Avino and C. Sala and A. Mugellini and V. Vulpis and S. Felis and L. Guasti and R. Sarzani and A. Bestetti and M. Vanasia and G. Gaudio and group, {the ESCAPE-IT Trial Investigators}",

note = "Export Date: 6 February 2018 Correspondence Address: Derosa, G.; Department of Internal Medicine and Therapeutics, University of PaviaItaly; email: giuseppe.derosa@unipv.it",

year = "2017",

doi = "10.1111/1755-5922.12235",

language = "English",

volume = "35",

pages = "47--54",

journal = "Cardiovascular Therapeutics",

issn = "1755-5914",

publisher = "Blackwell Publishing Ltd",

number = "1",

}

TY - JOUR

T1 - Efficacy and safety of two dosages of canrenone as add-on therapy in hypertensive patients taking ace-inhibitors or angiotensin II receptor blockers and hydrochlorothiazide at maximum dosage in a randomized clinical trial: The ESCAPE-IT trial

AU - Derosa, G.

AU - Maffioli, P.

AU - D'Avino, M.

AU - Sala, C.

AU - Mugellini, A.

AU - Vulpis, V.

AU - Felis, S.

AU - Guasti, L.

AU - Sarzani, R.

AU - Bestetti, A.

AU - Vanasia, M.

AU - Gaudio, G.

AU - group, the ESCAPE-IT Trial Investigators

N1 - Export Date: 6 February 2018 Correspondence Address: Derosa, G.; Department of Internal Medicine and Therapeutics, University of PaviaItaly; email: giuseppe.derosa@unipv.it

PY - 2017

Y1 - 2017

KW - Angiotensin II receptor blockers

KW - Angiotensin-converting enzyme inhibitors

KW - Canrenone

KW - Hydrochlorothiazide

KW - Hypertension

KW - aldosterone

KW - angiotensin receptor antagonist

KW - brain natriuretic peptide

KW - canrenone

KW - creatinine

KW - dipeptidyl carboxypeptidase inhibitor

KW - galectin 3

KW - hydrochlorothiazide

KW - potassium

KW - triacylglycerol

KW - urea

KW - uric acid

KW - angiotensin 1 receptor antagonist

KW - antihypertensive agent

KW - biological marker

KW - mineralocorticoid antagonist

KW - thiazide diuretic agent

KW - add on therapy

KW - Article

KW - blood pressure

KW - controlled study

KW - drug dose comparison

KW - drug efficacy

KW - drug safety

KW - drug tolerability

KW - drug withdrawal

KW - essential hypertension

KW - estimated glomerular filtration rate

KW - female

KW - glucose blood level

KW - heart rate

KW - human

KW - insulin resistance

KW - major clinical study

KW - male

KW - multicenter study

KW - open study

KW - parallel design

KW - phase 4 clinical trial

KW - priority journal

KW - pulse pressure

KW - randomized controlled trial

KW - side effect

KW - urea blood level

KW - aged

KW - blood

KW - clinical trial

KW - combination drug therapy

KW - comparative study

KW - drug effects

KW - hypertension

KW - Italy

KW - middle aged

KW - pathophysiology

KW - time factor

KW - treatment outcome

KW - Aged

KW - Angiotensin II Type 1 Receptor Blockers

KW - Angiotensin-Converting Enzyme Inhibitors

KW - Antihypertensive Agents

KW - Biomarkers

KW - Blood Pressure

KW - Drug Therapy, Combination

KW - Female

KW - Humans

KW - Male

KW - Middle Aged

KW - Mineralocorticoid Receptor Antagonists

KW - Sodium Chloride Symporter Inhibitors

KW - Time Factors

KW - Treatment Outcome

U2 - 10.1111/1755-5922.12235

DO - 10.1111/1755-5922.12235

M3 - Article

VL - 35

SP - 47

EP - 54

JO - Cardiovascular Therapeutics

JF - Cardiovascular Therapeutics

SN - 1755-5914

IS - 1

ER -

Access to Document

10.1111/1755-5922.12235

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85004125517&doi=10.1111%2f1755-5922.12235&partnerID=40&md5=ee2f0a9c4b967847cbb7f05f3d33f9c1